MannKind Entered into an Agreement with Zealand to Acquire V-Go Insulin Delivery Device for the Treatment of Diabetes
Shots:
- The companies collaborated to acquire V-Go for $10M up front & an additional sales-based milestones along with the cost of certain inventory. The transaction is expected to close in May 2022
- Following the acquisition of VGo, MannKind will be able to expand its portfolio, reinforce its commitment to offer new dietary diabetes & positioning its endocrine business for additional growth. The agreement is part of Zealand’s strategy to seek partners for commercial and late-stage assets while focusing on R&D
- V-Go is a wearable insulin delivery device that helps to manage blood sugar in everyday situations. V-Go is a patch-like device that avoids the need for several daily doses and is designed to be patient-friendly
Ref: Globenewswire | Image: MannKind
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
